The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas
Official Title: Phase II Trial of Bevacizumab in Patients With Recurrent or Progressive Meningiomas
Study ID: NCT01125046
Brief Summary: RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This phase II trial is studying how well bevacizumab works in treating patients with recurrent or progression meningiomas.
Detailed Description: PRIMARY OBJECTIVES: I. To determine the efficacy of bevacizumab in patients with recurrent or progressive benign and atypical/malignant meningiomas, despite prior therapy, as measured by six-month progression-free survival. SECONDARY OBJECTIVES: I. To describe the response rate and overall-survival in this patient population. II. To evaluate the safety profile of bevacizumab in patients with recurrent meningiomas. III. To perform an exploratory study in patients with hemangioblastoma and hemangiopericytoma. IV. To assess tissue for VEGF and VEGFR to correlate with response. An exploratory analysis of HER-2 will be performed. OUTLINE: Patients receive bevacizumab IV over 30-90 minutes every 2 weeks for 6 months. Patients may then receive bevacizumab IV every 3 weeks for up to 12 months. Treatment continues in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed every 3 months for 2 years.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Northwestern University, Chicago, Illinois, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Columbia University Medical Center, New York, New York, United States
University of Virginia, Charlottesville, Virginia, United States
University of Washington, Seattle, Washington, United States
Name: Priya Kumthekar, MD
Affiliation: Northwestern University
Role: PRINCIPAL_INVESTIGATOR